Eli Lil­ly touts PhI­II mirik­izum­ab win in Crohn’s de­spite woes in oth­er con­di­tions

Eli Lil­ly said its an­ti-in­flam­ma­to­ry med­i­cine mirik­izum­ab helped about half of peo­ple with Crohn’s dis­ease en­ter re­mis­sion af­ter one year in a Phase III study …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER